ClinicalTrials.gg
CompletedNCT00394745Updated Feb 24, 2017

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

A Phase 3 interventional study of Valsartan in Hypertension and Metabolic Syndrome, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
119th of 139
45 · median 198
Started
2005
with 12 others
Phase 3
53 of 140
none open now
Registered
61st of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 119th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2005, is one of 53 in phase 3, and was the 61st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.

03

Conditions studied

  • Hypertension
  • Metabolic Syndrome

Keywords

  • Hypertension, Metabolic Syndrome, lipid subfractions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients >= 18 years of age at Visit 1
  • Hypertension (systolic blood pressure >= 140 mmHg and \< 170 mmHg and/or diastolic blood pressure >= 90 mmHg and \< 105 mmHg
  • Elevated triglycerides
  • Metabolic syndrome as defined by Adult Treatment Panel III criteria

Exclusion criteria

Exclusion Criteria:

  • MSSBP >= 170 mmHg and/or MSDBP >= 105 mmHg at any time between Visit 1 and Visit 2
  • Diabetes mellitus
  • Patients treated with lipid lowering drugs in the last 6 weeks prior to Visit 1
  • A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, , stroke, and peripheral artery disease, heart failure II - IV Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of valsartan 320 mg on small, dense low density lipoprotein (LDL) subfractions in hypertensive patients with metabolic syndrome.

Secondary outcomes

  1. To evaluate the effect of valsartan 320 mg on further lipid subfractions and enzymes related to the lipoprotein metabolism.

  2. To evaluate the effect of valsartan 160-320 mg on blood pressure and pulse rate.

  3. To assess the safety and tolerability of valsartan 160-320mg.

07

Study locations

2 sites
  • Investigative Centers, Germany
  • Novartis
    Basel, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2006
First posted
Nov 1, 2006
Start
Nov 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00394745
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Nov 1, 2006
Start date
Nov 2005
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Feb 24, 2017

Study contacts

Novartis + 41 61 324 1111 Basel
study director · Novartis Basel+ 41 61 324 1111
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion